HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+1.26%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.53B
AUM Growth
+$2.53B
(+6.8%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
4.52%
Top 10 Holdings %
Top 10 Hldgs %
46.8%
Holding
68
New
20
Increased
18
Reduced
11
Closed
15
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$115M |
| 2 |
Humana
HUM
|
$103M |
| 3 |
Elanco Animal Health
ELAN
|
$97.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
$91.3M |
| 5 |
Abbott
ABT
|
$86.2M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$136M |
| 2 |
Haemonetics
HAE
|
$121M |
| 3 |
AGN
Allergan plc
AGN
|
$90.4M |
| 4 |
DexCom
DXCM
|
$87M |
| 5 |
Medtronic
MDT
|
$86.8M |
Sector Composition
| 1 | Healthcare | 93.16% |
| 2 | Technology | 1.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$13.8B
| $200M | 7.77% | 2,371,390 +855,300 | +56% | +$72.2M |
|
|
2
Humana
HUM
$36.5B
| $171M | 6.64% | 644,860 +386,720 | +150% | +$103M |
|
|
3
Edwards Lifesciences
EW
$47.8B
| $115M | 4.46% | +622,230 | New | +$115M |
|
4
Merck
MRK
$210B
| $108M | 4.2% | 1,292,410 +35,600 | +3% | +$2.99M |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $108M | 4.2% | 1,032,270 +140,280 | +16% | +$14.7M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $98.7M | 3.83% | 538,440 +199,670 | +59% | +$36.6M |
|
|
7
Elanco Animal Health
ELAN
$9.12B
| $97.3M | 3.78% | +2,879,010 | New | +$97.3M |
|
8
UnitedHealth
UNH
$281B
| $97M | 3.76% | 397,440 -159,120 | -29% | -$38.8M |
|
|
9
Abbott
ABT
$231B
| $96.2M | 3.73% | 1,144,160 +1,024,690 | +858% | +$86.2M |
|
|
10
Bristol-Myers Squibb
BMY
$96B
| $91.3M | 3.54% | +2,012,650 | New | +$91.3M |
|
|
NVRO
11
DELISTED
NEVRO CORP.
NVRO
| $79.6M | 3.09% | 1,227,730 +970,740 | +378% | +$62.9M |
|
12
Danaher
DHR
$147B
| $72.6M | 2.82% | 507,840 -542,880 | -52% | -$77.6M |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $67.2M | 2.61% | 2,793,670 +802,341 | +40% | +$19.3M |
|
14
Boston Scientific
BSX
$156B
| $63.2M | 2.45% | 1,471,370 +174,410 | +13% | +$7.5M |
|
|
XENT
15
DELISTED
Intersect ENT, Inc
XENT
| $63.2M | 2.45% | 2,775,895 +203,985 | +8% | +$4.64M |
|
|
CVRS
16
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $59.5M | 2.31% | 19,981,655 | – | – |
|
|
AMRN
17
Amarin Corp
AMRN
$311M
| $59.1M | 2.29% | +3,047,910 | New | +$59.1M |
|
18
HCA Healthcare
HCA
$94.5B
| $56.7M | 2.2% | 419,330 +272,520 | +186% | +$36.8M |
|
|
19
Medtronic
MDT
$119B
| $56.3M | 2.19% | 578,300 -890,890 | -61% | -$86.8M |
|
20
Align Technology
ALGN
$10.3B
| $56.2M | 2.18% | +205,510 | New | +$56.2M |
|
21
Charles River Laboratories
CRL
$8.04B
| $51.7M | 2.01% | +364,413 | New | +$51.7M |
|
22
Gilead Sciences
GILD
$140B
| $51.6M | 2% | 763,300 +139,810 | +22% | +$9.45M |
|
|
BLUE
23
DELISTED
bluebird bio
BLUE
| $46.8M | 1.82% | 368,090 +65,200 | +22% | +$8.29M |
|
24
Elevance Health
ELV
$71.8B
| $42.7M | 1.66% | +151,220 | New | +$42.7M |
|
|
25
Haemonetics
HAE
$2.63B
| $42.1M | 1.64% | 350,190 -1,007,220 | -74% | -$121M |
|